A phase IIb multicentric controlled trial was developed to assess TG4010 –an active targeted immunotherapy based on a viral MVA vector which codes for MUC1 tumor-associated antigen and interleukine 2 –in combination with first-line chemotherapy in patients with advanced NSCLC. This evidence concerns the gene MUC1 and non-small cell lung carcinoma.